Public Health is a multidisciplinary field that focuses on promoting and protecting the health of entire populations through disease prevention, health promotion, and health equity. Vaccines play a crucial role in public health efforts by preventing infectious diseases, reducing the burden of illness and death, and promoting community immunity.
One of the primary goals of public health is to prevent the spread of infectious diseases through vaccination programs. By immunizing large segments of the population against common pathogens, such as measles, influenza, and polio, public health authorities can reduce the incidence of disease outbreaks and prevent the spread of infectious agents within communities.
Vaccination programs are typically implemented through national or regional immunization schedules, which recommend the timing and doses of vaccines for different age groups and populations. These schedules are based on scientific evidence, epidemiological data, and public health priorities, and are regularly updated to reflect changes in disease prevalence, vaccine effectiveness, and emerging infectious threats.
In addition to preventing infectious diseases, vaccines also offer other benefits to public health. They can reduce healthcare costs by preventing expensive medical treatments and hospitalizations associated with vaccine-preventable diseases. They also help to protect vulnerable populations, such as infants, elderly individuals, and those with weakened immune systems, who may be at higher risk of complications from infectious diseases. Public health authorities play a critical role in promoting vaccination as a safe, effective, and essential component of preventive medicine. They work to educate the public about the importance of vaccination, address concerns and misconceptions about vaccines, and ensure equitable access to vaccines for all populations.
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Tubercular disease in children: Optimizing treatment strategies through disease insights
Elena Chiappini, University of Florence, Italy
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe
Title : Racial disparities in pediatric pneumonia in Brazil: The role of structural racism forging inequalities in acess to vaccines
Livia Daflon Silva, Federal University of State of Rio de Janeiro, Brazil
Title : Capillary electrophoresis for adjuvanted multivalent recombinant vaccine purity determination
Ashley Prout, Merck, United States